Post-marketing studies of newly approved drugs contribute little to safety aspects: Tufts report

摘要

While drug developers over the past six years have stepped up the number of postmarketing studies they conduct on newly approved medicines,sponsors feel that those studies have contributed little to their understanding of safety,efficacy,or quality,according to a recently completed assessment by the Tufts Center for the Study of Drug Development.